EUDA Health Holdings Limited (EUDA) vs Harvard Bioscience, Inc. (HBIO)
A side-by-side comparison of EUDA Health Holdings Limited and Harvard Bioscience, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EUDA
EUDA Health Holdings Limited
$19.39HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
HBIO
Harvard Bioscience, Inc.
$8.56HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — EUDA vs HBIO
growth of $100 · dividends reinvested · last 5yEUDA -91.0% (-38.3%/yr)HBIO -87.9% (-34.4%/yr)HBIO compounded faster over this window
EUDA HBIO
EUDA vs HBIO: by the numbers
- •HBIO is the larger company ($39M vs $36M market cap).
- •Both run net losses; HBIO's is the smaller (-11.86% vs -40.49% net margin).
- •Both shrank revenue over the past five years; HBIO's decline was smaller (-4.62% vs -5.13% CAGR).
Metrics side by side
Valuation
| Metric | EUDA | HBIO |
|---|---|---|
| Forward P/E | 12.12 | N/A |
| P/S ratio | 3.08 | 0.44 |
| P/B ratio | N/A | 5.20 |
| EV / EBITDA | N/A | 10.54 |
Profitability
| Metric | EUDA | HBIO |
|---|---|---|
| Gross margin | 41.73% | 58.16% |
| Operating margin | -36.42% | 1.17% |
| Net margin | -40.49% | -11.86% |
| ROE | N/A | -140.36% |
| ROIC | N/A | 1.99% |
Growth (annualized)
| Metric | EUDA | HBIO |
|---|---|---|
| Revenue CAGR (5Y) | -5.13% | -4.62% |
| Total return CAGR (5Y) | N/A | -34.33% |
Frequently asked
- Which has grown faster, EUDA or HBIO?
- Neither grew: over the past five years both shrank revenue, with HBIO's decline the smaller — EUDA at a -5.13% CAGR versus HBIO at -4.62%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.